Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 3

Sponsor Class

OTHER 3INDUSTRY 3NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 381Other hematologic neoplasm 215Thoracic 155CNS 78Sarcoma 55Plasma cell 40Genitourinary 37Myeloid 35Other solid neoplasm 29Gynecologic 24Dermatologic 24Breast 16Gastrointestinal 13Classical hematology 10Endocrine 8Head & Neck 5Tumor-Agnostic 3Other neoplasm 3NET 3Other 1

Conditions

Neoplasms, Unknown Primary 1Neoplasms 1Neoplasm Metastasis 1

Interventions

Surveys and Questionnaires 70Blood Specimen Collection 48Radiotherapy 39Magnetic Resonance Spectroscopy 35pembrolizumab 31Gemcitabine 30Bevacizumab 30Nivolumab 29Carboplatin 29Radiosurgery 27Standard of Care 26Oxaliplatin 26Capecitabine 25Paclitaxel 24Interviews as Topic 24Cisplatin 24Fluorouracil 23Erlotinib Hydrochloride 22Everolimus 19Irinotecan 18Trastuzumab 17Methods 17Exercise 17Docetaxel 17Biopsy 17Cyclophosphamide 16Educational Status 15Sorafenib 14Ipilimumab 14Fluorodeoxyglucose F18 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Etoposide × Tumor-Agnostic × Clear all
NCT00936156 2020-06-29

Treatment of High-Risk Cerebral Primitive Neuroectodermal Tumors in Children Aged Over 5 Years

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2 Completed
68 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT00193596 2013-05-03

Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site

SCRI Development Innovations, LLC

Phase 3 Completed
198 enrolled 7 charts
Tumor-Agnostic

Neoplasms, Unknown Primary

NCT00165451 2011-07-07

A Trial of Thalidomide, Celecoxib, Etoposide and Cyclophosphamide in Patients With Relapsed or Progressive Cancer

Dana-Farber Cancer Institute

Phase 2 Completed
20 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡